Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Christopher Kenney & Joseph Jankovic. (2007) Rotigotine transdermal patch in the treatment of Parkinson’s disease and restless legs syndrome. Expert Opinion on Pharmacotherapy 8:9, pages 1329-1335.
Read now
Read now
Articles from other publishers (22)
Degirmenci Husnu, Bakirci Eftal Murat & Hamur Hikmet. (2020) Cardiac Effects of Parkinson’s Disease. Open Journal of Parkinson's Disease and Treatment, pages 006-007.
Crossref
Crossref
Dan Luo, Maarten Reith & Aloke K. Dutta. 2020. Diagnosis and Management in Parkinson's Disease. Diagnosis and Management in Parkinson's Disease
445
460
.
Khalid Orayj & Emma Lane. (2019) Patterns and Determinants of Prescribing for Parkinson’s Disease: A Systematic Literature Review. Parkinson's Disease 2019, pages 1-40.
Crossref
Crossref
Eun-Hye Lee, Sang-Mi Kim, Chun-Hyung Kim, Suvarna H. Pagire, Haushabhau S. Pagire, Hee Yong Chung, Jin Hee Ahn & Chang-Hwan Park. (2019) Dopamine neuron induction and the neuroprotective effects of thyroid hormone derivatives. Scientific Reports 9:1.
Crossref
Crossref
Urmila Maitra & Lukasz Ciesla. (2019)
Using
Drosophila
as a platform for drug discovery from natural products in Parkinson's disease
. MedChemComm 10:6, pages 867-879.
Crossref
Crossref
Vaibhav Walia, Ashish Gakkhar & Munish Garg. 2019. Handbook of Research on Critical Examinations of Neurodegenerative Disorders. Handbook of Research on Critical Examinations of Neurodegenerative Disorders
252
273
.
Robert A. Marino & Ron Levy. (2019) Differential effects of D1 and D2 dopamine agonists on memory, motivation, learning and response time in non-human primates. European Journal of Neuroscience 49:2, pages 199-214.
Crossref
Crossref
Panchanan Maiti, Jayeeta Manna & Gary L. Dunbar. (2017) Current understanding of the molecular mechanisms in Parkinson's disease: Targets for potential treatments. Translational Neurodegeneration 6:1.
Crossref
Crossref
Min-Ho Nam, Moosung Park, Hyeri Park, Youngjae Kim, Seulki Yoon, Vikram Shahaji Sawant, Ji Won Choi, Jong-Hyun Park, Ki Duk Park, Sun-Joon Min, C. Justin Lee & Hyunah Choo. (2017) Indole-Substituted Benzothiazoles and Benzoxazoles as Selective and Reversible MAO-B Inhibitors for Treatment of Parkinson’s Disease. ACS Chemical Neuroscience 8:7, pages 1519-1529.
Crossref
Crossref
Hayley J. MacDonald, Cathy M. Stinear, April Ren, James P. Coxon, Justin Kao, Lorraine Macdonald, Barry Snow, Steven C. Cramer & Winston D. Byblow. (2016) Dopamine Gene Profiling to Predict Impulse Control and Effects of Dopamine Agonist Ropinirole. Journal of Cognitive Neuroscience 28:7, pages 909-919.
Crossref
Crossref
F.I. Tarazi, Z.T. Sahli, M. Wolny & S.A. Mousa. (2014) Emerging therapies for Parkinson's disease: From bench to bedside. Pharmacology & Therapeutics 144:2, pages 123-133.
Crossref
Crossref
Manuela Jörg, Agnieszka A. Kaczor, Frankie S. Mak, Kiew Ching K. Lee, Antti Poso, Neil D. Miller, Peter J. Scammells & Ben Capuano. (2014)
Investigation of novel ropinirole analogues: synthesis, pharmacological evaluation and computational analysis of dopamine D
2
receptor functionalized congeners and homobivalent ligands
. MedChemComm 5:7, pages 891-898.
Crossref
Crossref
Mark Johnson & Aloke Dutta. 2013. Emerging Drugs and Targets for Parkinson’s Disease. Emerging Drugs and Targets for Parkinson’s Disease
126
148
.
K.A. Stockwell, D.K.A. Scheller, L.A. Smith, S. Rose, M.M. Iravani, M.J. Jackson & P. Jenner. (2010) Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or l-DOPA in MPTP-treated common marmosets. Experimental Neurology 221:1, pages 79-85.
Crossref
Crossref
Masatoshi Inden, Yoshihisa Kitamura, Aya Tamaki, Takashi Yanagida, Tomonori Shibaike, Atsuko Yamamoto, Kazuyuki Takata, Hiroyuki Yasui, Takahiro Taira, Hiroyoshi Ariga & Takashi Taniguchi. (2009) Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice. Neurochemistry International 55:8, pages 760-767.
Crossref
Crossref
Mauricette Brocco, Anne Dekeyne, Mariusz Papp & Mark J. Millan. (2006) Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors. Behavioural Pharmacology 17:7, pages 559-572.
Crossref
Crossref
R. Moldzio, K. Radad, J. C. Duvigneau, B. Kranner, C. Krewenka, C. Piskernik & W. D. Rausch. (2006) Glutamate-induced cell death and formation of radicals can be reduced by lisuride in mesencephalic primary cell culture. Journal of Neural Transmission 113:9, pages 1095-1105.
Crossref
Crossref
Mark J. Millan. (2006) Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacology & Therapeutics 110:2, pages 135-370.
Crossref
Crossref
S. Badarny, A. Stern, Z. Susel, S. Honigman & S. Hocherman. (2006) Effect of ropinirole on visuo-motor test in newly diagnosed Parkinson's disease patients. Acta Neurologica Scandinavica 0:0, pages 060321023242006.
Crossref
Crossref
Fang Du, Rui Li, Yuangui Huang, Xuping Li & Weidong Le. (2005) Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons. European Journal of Neuroscience 22:10, pages 2422-2430.
Crossref
Crossref
E Lim. (2005) A Walk Through the Management of Parkinson’s Disease. Annals of the Academy of Medicine, Singapore 34:2, pages 188-195.
Crossref
Crossref
Tianhong Pan, Wenjie Xie, Joseph Jankovic & Weidong Le. (2005) Biological effects of pramipexole on dopaminergic neuron-associated genes: relevance to neuroprotection. Neuroscience Letters 377:2, pages 106-109.
Crossref
Crossref